Lin Chenyu, Galal Ahmed, Rizzieri David, Chawla Sant, Lee Seung T, Georgy Angela, Dabovic Kristina, Strack Thomas, McKinney Matthew
Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Novant Health Cancer Institute, Charlotte, North Carolina, USA.
Cancer Invest. 2023 Jan 31:1-10. doi: 10.1080/07357907.2022.2162073.
MT-3724 is an engineered direct-kill immunotoxin comprised of a CD20-specific scFv fused to a Shiga-like toxin subunit. In this phase IIa study, eight patients with relapsed diffuse large B-cell lymphoma were treated with MT-3724 combined with gemcitabine and oxaliplatin (GEMOX). The objective response rate was 85.7%, with a median duration of response of 2.2 months. The 12-month overall survival and progression-free survival were 71.4% and 28.6%, respectively. Two patients experienced grade 2 capillary leak syndrome (CLS). Combination therapy with MT-3724 and GEMOX demonstrated an early efficacy signal but was limited by the incidence of CLS.
MT-3724是一种经过改造的直接杀伤免疫毒素，由与志贺样毒素亚基融合的CD20特异性单链抗体片段组成。在这项IIa期研究中，8例复发的弥漫性大B细胞淋巴瘤患者接受了MT-3724联合吉西他滨和奥沙利铂（GEMOX）治疗。客观缓解率为85.7%，中位缓解持续时间为2.2个月。12个月的总生存率和无进展生存率分别为71.4%和28.6%。两名患者出现2级毛细血管渗漏综合征（CLS）。MT-3724与GEMOX的联合治疗显示出早期疗效信号，但受CLS发生率的限制。
